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Abstract
Background: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong
antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a
phase 1/2 clinical study of this anti-inflammatory drug for the treatment of recurrent WHO grade 3 and 4 astrocytic
gliomas in adults.
Methods: 10 patients with advanced recurrent anaplastic astrocytoma (n = 2) or glioblastoma (n = 8) aged 32-62 years
were recruited prior to the planned interim analysis of the study. Subjects were randomly assigned to daily doses of 1.5,
3, 4.5, or 6 grams of oral sulfasalazine, and treated until clinical or radiological evidence of disease progression or the
development of serious or unbearable side effects. Primary endpoints were the evaluation of toxicities according to the
CTCAE v.3.0, and the observation of radiological tumor responses based on MacDonald criteria.
Results: No clinical response was observed. One tumor remained stable for 2 months with sulfasalazine treatment, at
the lowest daily dose of the drug. The median progression-free survival was 32 days. Side effects were common, as all
patients developed grade 1-3 adverse events (mean: 7.2/patient), four patients developed grade 4 toxicity. Two patients
died while on treatment or shortly after its discontinuation.
Conclusion: Although the proper influence of sulfasalazine treatment on patient outcome was difficult to ascertain in
these debilitated patients with a large tumor burden (median KPS = 50), ISRCTN45828668 was terminated after its
interim analysis. This study urges to exert cautiousness in future trials of Sulfasalazine for the treatment of malignant
gliomas.
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Background
Despite a wealth of preclinical and clinical research, treat-
ment options for malignant gliomas remain scarce, and
median survival of patients barely reaches 15 months
despite surgery, radiation and chemotherapy [1].
Among several recently discovered biochemical anoma-
lies of malignant gliomas, transcription factor NF-kappaB
has emerged as a major molecular determinant of tumor
progression and treatment resistance [2]. It is constitu-
tively activated in most high-grade gliomas [3-8], where it
promotes the expression of various pro-invasion, anti-
apoptotic and cell-cycle related genes [7,9,10]. Inactiva-
tion of NF-kappaB blocks glioma growth in in vitro and in
vivo  models, and increases their response to radiation,
chemotherapy and suicide gene therapy [11-13].
Sulfasalazine, an anti-inflammatory drug, is a known
inhibitor of the multimeric kinase complex IKK that is
essential to the canonical pathway of NF-kappaB activa-
tion [14]. Additionally, this drug inhibits the x(c)-cystine/
glutamate antiporter, an amino-acid transporter protein
that is essential for the survival of glial cells [15,16].
Although there is presently a lack of pharmacological data
that proves sulfasalazine penetrates the blood brain bar-
rier, it was shown to exert a clear anti-tumor effect on
rodent and human glioblastomas transplanted in the
brain of nude mice [2,12,15].
Because of these promising preclinical data and as Sul-
fasalazine has been used clinically for over 4 decades for
the treatment of colon and joint inflammatory diseases
and causes little toxicity at daily doses up to 6 g/day [17],
we initiated ISRCTN45828668, a double-blinded, pro-
spective, phase 1/2 clinical trial of Sulfasalazine for the
treatment of recurrent or progressive high-grade gliomas
[18]. This study was designed as a phase 2, randomized,
study looking for tumor responses. Given the fact that no
specific safety data was available on the use of Sulfasala-
zine in the setting of malignant glial tumors however, the
study also looked for treatment toxicities as a primary
objective, and an interim review of treatment safety was
planned to occur after an accrual of 10 patients.
The results of this interim review are reported according to
the GNOSIS recommendations in neuro-oncology [19].
Methods
Study Design
The protocol of ISRCTN45828668, a prospective, rand-
omized, double-blinded single-center phase 1-2 study of
Sulfasalazine for the treatment of recurrent or progressive
high-grade astrocytic gliomas, has been published previ-
ously [18]. Briefly, a total of twenty adult patients (over 18
years old), with progressive astrocytic malignant glioma
despite surgery, radiation therapy and a first line of chem-
otherapy and with a life expectancy of at least 2 month
were scheduled for recruitment. After signing an informed
consent, patients underwent a clinical, radiological (base-
line MRI) and biological examination and were evaluated
with respect to our inclusion and exclusion criteria [see
additional file 1: Table S1]. Upon enrollment, subjects
were randomly assigned to one of four dose regimens of
Sulfasalazine, using a randomization software (S-Plus
v6.2, Insightful Corp., MathSoft, Seattle, WA, USA). Con-
tinuous daily doses of 1.5, 3, 4, or 6 g were taken orally
t.i.d. until complete remission, evidence of progression or
drug intolerance. Both the patients and the treating physi-
cians were blinded to the individual dosages of sulfasala-
zine. Drug preparations were conditioned at the CHU of
Liege Pharmacy department, and provided in the form of
unremarkable capsules allowing both the patient and the
physicians to remain blinded with respect to the individ-
ual dosage.
Given that Sulfasalazine safety had never been assessed in
the context of malignant glial tumors however, the two
primary endpoints of ISRCTN45828668 were the assess-
ment of treatment toxicity and tumor response as meas-
ured according to modified (volumetric) MacDonald's
criteria [20]. Overall survival and progression-free survival
were secondary endpoints. To enforce the assessment of
treatment safety, an independent, interim analysis of drug
safety was scheduled and conducted after the accrual of
ten patients. In order to facilitate the interim analysis of
the data by the review committee, the randomization
algorithm was weighted so that 8 of the first 10 patients
received either the lowest or the highest drug dosage.
The protocol was sponsored by the Department of Neuro-
surgery, University Hospital of Liège, Belgium. It was
reviewed and approved by the Ethics Committee of the
Faculty of Medicine of the University of Liège, underwent
review and approval by Belgian Federal Health Authorities
(authorization reference 548/03/05) and was granted the
European Trial database (EudraCT) number 2004-
004392-11.
Patients under 18 years old, or with anaplastic oligoden-
droglioma (WHO grade 3), allergy to sulfa drugs, porphy-
ria, G-6-PD, kidney or liver deficiency or psychiatric
disorder deemed incompatible with compliance to the
study were excluded, as well as lactating or pregnant
women.
Blood samples were analyzed every 15 days following
treatment initiation, and follow-up visits-including clini-
cal examination, history, MRI scan and urinalysis - were
performed every 30 days. Adverse events were evaluated
according to the NCI common toxicity criteria (CTCAE)BMC Cancer 2009, 9:372 http://www.biomedcentral.com/1471-2407/9/372
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version 3.0). Volume changes were measured on gadolin-
ium-enhanced T1 weighted MPR images, using the Splicer
software v 2.6 (Surgical Planning Laboratory, Brigham
and Women's Hospital, Boston, MA [21]).
Statistical analysis
Results were expressed as means ± standard deviations
(SDs) for quantitative variables, while frequencies and
proportions (%) were used for categorical variables. The
non-parametric correlation coefficient of Spearman was
calculated for measuring the association between two
quantitative variables. Survival curves were determined by
the Kaplan-Meier method and compared by the log-rank
test. Calculations were always carried out on the maxi-
mum number of data available. Missing data were not
replaced. Results were considered to be significant at the
5% critical level (p < 0.05). Data analysis was carried out
using SAS (version 9.1 for Windows) and S-PLUS (version
6.2) statistical packages by AA and SV (Department of
Medical Statistics, University of Liège, Belgium).
Immunochemistry and MGMT promoter analysis
Histology of the tumor samples obtained at the time of
initial surgery was reviewed in all patients by an experi-
enced neuropathologist (MD). NF-kappaB p65 staining of
patient 6's tumor was performed using a monoclonal anti-
body to p65 (Santa Cruz Biotechnology) and as described
previously [2]. MGMT promoter analysis was performed
by Oncomethylome Sciences (Liege, Belgium), as
described previously [22].
Results
Patient demographics
The relevant demographic and clinical characteristics of
the patients included in the study are listed in [see addi-
tional file 2: Table S2A]. At the time of interim analysis,
performed as scheduled, nine males and one female
patient, aged 32-62 yr (median: 53.5) had been enrolled
in and completed the study between May, 2005 and Janu-
ary, 2007. All patients had undergone surgery, standard
radiation therapy (54-60 Gy) and a course of chemother-
apy with alkylating agents prior to their inclusion in the
present study. Nine patients were thus on temozolomide
chemotherapy prior to their inclusion in the study. One
patient was on a BCNU regimen. All patients had been off
these cytotoxic medications for at least 4 weeks prior to
the initiation of their Sulfasalazine treatment, and none
had manifested severe side effects. Patient #4 and 6 had
however experienced mild headaches and nausea while
on temozolomide, and patient #7 had presented tran-
siently decreased white cell counts on this regimen. All
patients were free of those symptoms at the time of inclu-
sion in ISRCTN45828668.
Eight patients had a diagnosis of recurrent glioblastoma
multiforme and two suffered progressive anaplastic astro-
cytomas. MGMT promoter methylation analysis, assessed
in all tumors at the time of initial resection, provided une-
quivocal results in 8 patients, and demonstrated a pro-
moter methylation in only one tumor (patient # 3). KPS
scores at the time of inclusion ranged from 40 to 70, with
a median of 50. The initial tumor volume was on average
67.7 ± 31.9 ml (range: 30.8 - 134 ml).
Primary objective #1: treatment-associated toxicity
Adverse events that occurred over the duration of the
study are reported in tables S2B [see additional file 2:
Table S2B] and S3 [see additional file 3], together with the
initial KPS of the patients and daily dose of Sulfasalazine
intake. All patients experienced adverse events (AEs) of
grade 1 to 3 (CTCAE V 3.0), with an average of 7.2 ± 2.6
(range 4 - 11, median 7.5). Four (40%) patients devel-
oped a grade 4 toxicity, two of whom subsequently devel-
oped grade 5 (i.e., lethal) SAEs. The number of adverse
events of grade 1 to 3 and the occurrence of adverse events
of grade 4 were not related to the dose of sulfasalazine (p
= 0.44 and p = 0.17 respectively). Both patients encoun-
tering grade 5 adverse events were in the 1.5 g/day dose (p
= 0.094).
Of the grade 1-3 AEs, 5 patients developed significant T2
MRI changes, believed to result from an increased peritu-
moral oedema and accompanied by increased cephalalgia
(Figure 1). Proteinuria was encountered in 6 patients dur-
ing sulfasalazine treatment. Bone marrow toxicity was
finally encountered in 4 patients (neutropenia in 2, lym-
Sulfaslazine-associated peritumor oedema Figure 1
Sulfaslazine-associated peritumor oedema. T2 MRI 
scans obtained at inclusion, prior to Sulfasalazine treatment 
in patient #4, and 8 days after the initiation of sulfaslaazine 
treatment (6 g/day). The images demonstrate an increased 
peritumoral oedema and the developing midline shift. This 
patient alo developed severe headaches and withdrew from 
the study.BMC Cancer 2009, 9:372 http://www.biomedcentral.com/1471-2407/9/372
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phopenia and thrombopenia in 1 patient each). Four
patients also presented reduced serum levels of the anti-
epileptic drugs sodium valproate (n = 4), phenytoin (n =
2) and carbamazepine (n = 1). No correlation was
observed between sulfasalazine dose and the occurrence
of these decreases.
Grade 4 AEs consisted of increased neurological deficits,
epilepsy, cognitive dysfunction, altered consciousness,
confusion, ataxia and one case of decreased sodium val-
proate and phenytoin serum levels. Death occurred in this
latter patient as the result of inhalation pneumonia, fol-
lowing status epilepticus, after four weeks of Sulfasalazine
treatment. Another patient developed a rapidly progres-
sive cognitive deterioration within 5 days of sulfasalazine
intake, followed by progressive loss of consciousness and
death within a month despite medication withdrawal.
Even though the initial KPS of these patients were 40 and
50 respectively at the time of inclusion, these adverse
events were considered as probably related to the study
drug.
Primary objective #2: Tumor response
Only one tumor appeared to be stabilized for two month
under sulfasalazine treatment (patient #3), whereas all
other lesions progressed. Defining tumoral growth as the
ratio between the final and initial tumor volumes, the
increase during the treatment duration was on average 2.0
± 0.7 (range: 1.4 - 3.2) and was highly significant (p <
0.0001). The growth was neither related to the dose of the
sulfasalazine treatment (r = 0.45, p = 0.22) nor to treat-
ment duration (r = -0.06, p = 0.88). The tumoral growth
rate per day was defined as the difference between the
final and the initial volume over the period of sulfasala-
zine treatment. The growth rate was on average 2.1 ± 1.8
ml/day (range: 0.4 - 5.9 ml/day, Figure 2) and was signif-
icantly different from 0 (p = 0.005). The growth rate was
not related to the dose (r = 0.26, p = 0.50).
Secondary objectives: Progression-free and overall survival
The overall survival was defined as the time (days)
between the initiation of the sulfasalazine treatment and
the death of the patient. Patients survived on average 100
± 76.9 days (range: 32 - 270 days, median: 70.5 days; Fig-
ure 3 and Table S2B [see additional file 2]). Treatment
was discontinued due to tumor growh (9 patients) and/or
side effects (2 patients) after a mean of 35 ± 25.7 days
(Progression Free Survival: median: 31.5 days, range: 5-
94).
After sulfaslazine discontinuation, one patient was reop-
erated, and 4 patients (including the latter) received a sal-
vage course of BCNU chemotherapy. The survival time
after the end of the sulfasalazine treatment was on average
65.2 ± 55.8 days (range: 0 - 176 days, median: 44.5 days).
Discussion
The ISRCTN45828668 study was designed to assess the
safety and potential efficacy of Sulfasalazine, an IKK and
X-cystine transporter inhibitor, for the treatment of recur-
rent astrocytic malignant gliomas.
As scheduled, an interim analysis of the outcome of the
first ten patients included in the study was performed
prior to the inclusion of the second half of the planned
study population. As described in the results section, this
interim analysis revealed a high incidence of serious side
effects as well as a lack of efficacy.
Several side effects were observed in our patients, two of
which are particularly relevant in the setting of neurosur-
gical patients. Five patients developed T2 MRI changes
characterized by an increase in the apparent peritumoral
edema. Sulfasalazine was previously reported to induce
encephalopathies and T2 MRI hyperintesities in rheuma-
tologic [23,24], or Crohn's disease patients [25] and to
cause intracranial hypertension [26]. It was also reported
to aggravate experimental auto-immune encephalomyeli-
tis, a phenomenon thought to result from immune effects
and hypersensitivity reactions to the drug [27]. None of
our patients, however, presented any rash or other sign of
sulfasalzine hypersensitivity. We thus suspect that sul-
fasalzine more directly increased the permeability of
(peri)tumoral vessels in our patients. Such an effect is
however unlikely to result from sulfasalazine-mediated
NF-kappaB inhibition, as this transcription factor is
known to contribute to the vascular leakage in response to
LPS and various cytokines [28]. More probably, inhibition
of the x(c)-cystine/glutamate antiport could reduce intra-
cellular gluthatione levels in endothelial cells and result in
blood-brain barrier dysfunction [29]. Whatever the exact
mechanism, and although tumor progression may also
have contributed to this effect, sulfasalazine treatment
induced a significant brain edema in 50% of our recurrent
glioma patients, which likely contributed to worsening of
their headaches and neurological condition.
Sulfasalzine treatment correlated with decreased serum
levels of anti-epileptic drugs in 5 patients, namely sodium
valproate (n = 5), phenytoin (n = 3) and carbamazepine
(n = 1). The cause of this side effect remains unclear, as we
did not find evidence of any correlation between sul-
fasalazine dosage and AED level decrease. Seizure activity
nevertheless increased in two of these patients, leading to
a worsening of their clinical condition and to the death
(by inhalation pneumonia) of one of them.
Tumor growth was at best unaffected in our patients fol-
lowing sulfasalazine treatment, in contrast to previous
reports of tumor growth inhibition in preclinical in vivo
models of human malignant gliomas [2,15]. Several fac-BMC Cancer 2009, 9:372 http://www.biomedcentral.com/1471-2407/9/372
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tors might contribute to this discrepancy. First, the small
number and large tumor burden of the patients analyzed
in this study may have missed or masked a limited drug
efficacy. Second, of the 8 tumors for which MGMT pro-
moter analysis could be performed, 7 (87.5%) were
unmethylated, a known factor of overall tumor resistance
against alkylating agent therapy [30]. Third, the overall
pharmacokinetics of sulfasalazine might differ between
mice and humans, and different routes of administration
were used in preclinical and clinical experiments (intra-
peritoneal injection in mice, oral use in humans). Fourth,
Sulfasalazine targets only one of several pathways to NF-
kappaB activation, which may result in malignant gliomas
escaping treatment effect by utilizing accessory NF-kap-
paB pathways. Interestingly, an immunohistochemistry to
p65 was performed on the tumor of the patient who was
re-operated after sulfasalazine cessation, and showed
abundant cytoplasmic and nuclear NF-kappaB reactivity.
These highly resistant and heterogeneous tumors could
thus rapidly develop mechanisms of resistance to sul-
fasalazine and/or IKK-independent routes of NF-kappaB
activation. Accordingly, PFS during sulfasalazine treat-
ment remained marginal. In addition, differences in NF-
kappaB-related pathways may exist between malignant
glioma cell lines, primary cultures of malignant glioma,
and malignant gliomas specimens [31]. Fifth, Sulfasala-
Tumor growth during Sulfasalazine treatment Figure 2
Tumor growth during Sulfasalazine treatment. A/Tumor growth between inclusion and sulfasalazine treatment arrest 
(volumes are provided in ml and were measured by segmentation on gadolinium-enhanced T1 MRI scans); B/Gadolinium-
enhanced T1 MRI scans of patient #05 at the time of inclusion and after 32 days of sulfasalzine treatment (6 g/day). The tumor 
volume has more than tripled over this period.BMC Cancer 2009, 9:372 http://www.biomedcentral.com/1471-2407/9/372
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zine is known to induce a release of adenosine from sev-
eral cell types [32], and adenosine is a know mitogen for
glial cells [33].
Overall, we did not evidence any objective clinical
response to sulfasalazine in this study, and on the con-
trary, observed some very fast tumor growths despite sul-
fasalazine treatment and the occurrence of serious adverse
events. The death of two patients during or shortly after
sulfasalazine treatment raises significant concerns about
the safety of this drug for the treatment of human malig-
nant gliomas, even if continued tumor progression in
these already debilitated patients (KPS of 40 and 50,
respectively) may have contributed to their deaths. In
agreement with the independent review committee of the
study, these serious adverse events and apparent lack of
therapeutic benefit led to the early termination of
ISRCTN445828668.
Conclusion
In conclusion, we strongly oppose the opinion, advocated
by several physician and patient support web sites and
preclinical reports, that sulfasalazine should be used rou-
tinely for the treatment of glioblastoma patients. We also
recommend to exert extreme care in the surveillance of gli-
oma patients included or to be included in other control-
led clinical trials that use this drug.
However, the strong preclinical evidence of NF-kappaB in
the growth and resistance of malignant gliomas remains
unaltered by this study, which only raises questions
regarding the value of Sulfasalazine as a clinically useful
NF-kappaB inhibitor. We thus encourage the develop-
ment of additional clinical trials that target this transcrip-
tion factor, using other more specific and/or more potent
pharmacological inhibitors of NF-kappaB that are cur-
rently being developed (reviewed in [34]).
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